IL114770A - Controlled release carriers of bioactive silica-based glass comprising biologically active molecules, method for their preparation and compositions containing them - Google Patents

Controlled release carriers of bioactive silica-based glass comprising biologically active molecules, method for their preparation and compositions containing them

Info

Publication number: IL114770A
Authority: IL; Israel
Prior art keywords: carrier; biologically active; active molecules; glass; gel
Prior art date: 1994-07-27

Application number

IL11477095A

Other languages

English (en)

Other versions

IL114770A0 (en

Original Assignee

Univ Pennsylvania

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-07-27

Filing date

1995-07-27

Publication date

2002-12-01

1995-07-27 Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania

1995-11-27 Publication of IL114770A0 publication Critical patent/IL114770A0/xx

2002-12-01 Publication of IL114770A publication Critical patent/IL114770A/en

Links

VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 title claims abstract description 130
239000011521 glass Substances 0.000 title claims abstract description 123
239000000377 silicon dioxide Substances 0.000 title claims abstract description 51
238000013270 controlled release Methods 0.000 title claims abstract description 42
230000000975 bioactive effect Effects 0.000 title claims abstract description 23
238000000034 method Methods 0.000 title claims description 91
239000000203 mixture Substances 0.000 title claims description 80
239000000969 carrier Substances 0.000 title claims description 22
238000002360 preparation method Methods 0.000 title claims description 6
239000011159 matrix material Substances 0.000 claims abstract description 76
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 51
238000007654 immersion Methods 0.000 claims description 46
239000003102 growth factor Substances 0.000 claims description 45
229910001868 water Inorganic materials 0.000 claims description 42
239000008187 granular material Substances 0.000 claims description 41
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
239000003814 drug Substances 0.000 claims description 36
108090000623 proteins and genes Proteins 0.000 claims description 36
229940079593 drug Drugs 0.000 claims description 35
102000004169 proteins and genes Human genes 0.000 claims description 35
-1 silicon alkoxide Chemical class 0.000 claims description 33
239000011575 calcium Substances 0.000 claims description 32
238000001035 drying Methods 0.000 claims description 32
230000000694 effects Effects 0.000 claims description 31
229910052791 calcium Inorganic materials 0.000 claims description 30
239000007943 implant Substances 0.000 claims description 25
230000004580 weight loss Effects 0.000 claims description 22
229910052710 silicon Inorganic materials 0.000 claims description 21
230000003115 biocidal effect Effects 0.000 claims description 20
239000002243 precursor Substances 0.000 claims description 20
239000010703 silicon Substances 0.000 claims description 19
239000003242 anti bacterial agent Substances 0.000 claims description 17
230000032683 aging Effects 0.000 claims description 15
230000008569 process Effects 0.000 claims description 15
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 14
230000007547 defect Effects 0.000 claims description 13
150000004703 alkoxides Chemical class 0.000 claims description 12
229910052681 coesite Inorganic materials 0.000 claims description 12
229910052906 cristobalite Inorganic materials 0.000 claims description 12
229910052682 stishovite Inorganic materials 0.000 claims description 12
229910052905 tridymite Inorganic materials 0.000 claims description 12
239000002253 acid Substances 0.000 claims description 11
102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 10
108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 10
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical group C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 10
239000011248 coating agent Substances 0.000 claims description 9
238000000576 coating method Methods 0.000 claims description 9
159000000007 calcium salts Chemical class 0.000 claims description 8
229910052698 phosphorus Inorganic materials 0.000 claims description 8
238000003756 stirring Methods 0.000 claims description 8
MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 claims description 7
238000012545 processing Methods 0.000 claims description 7
238000013268 sustained release Methods 0.000 claims description 7
239000012730 sustained-release form Substances 0.000 claims description 7
230000004071 biological effect Effects 0.000 claims description 6
239000008367 deionised water Substances 0.000 claims description 6
229910021641 deionized water Inorganic materials 0.000 claims description 6
238000002156 mixing Methods 0.000 claims description 6
239000012300 argon atmosphere Substances 0.000 claims description 5
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 4
238000011049 filling Methods 0.000 claims description 4
239000012530 fluid Substances 0.000 claims description 4
150000002500 ions Chemical class 0.000 claims description 4
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 claims description 3
238000011065 in-situ storage Methods 0.000 claims description 3
230000002459 sustained effect Effects 0.000 claims description 2
230000000202 analgesic effect Effects 0.000 claims 5
239000003795 chemical substances by application Substances 0.000 claims 3
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 2
101150089916 Miox gene Proteins 0.000 claims 1
239000000499 gel Substances 0.000 description 93
239000000463 material Substances 0.000 description 72
229960003165 vancomycin Drugs 0.000 description 63
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 62
108010059993 Vancomycin Proteins 0.000 description 61
210000000988 bone and bone Anatomy 0.000 description 61
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 61
239000000243 solution Substances 0.000 description 49
239000008279 sol Substances 0.000 description 45
101710162629 Trypsin inhibitor Proteins 0.000 description 31
229940122618 Trypsin inhibitor Drugs 0.000 description 31
239000002753 trypsin inhibitor Substances 0.000 description 31
230000015572 biosynthetic process Effects 0.000 description 24
239000000523 sample Substances 0.000 description 24
ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 23
239000005313 bioactive glass Substances 0.000 description 22
238000010348 incorporation Methods 0.000 description 21
239000011148 porous material Substances 0.000 description 20
229910052588 hydroxylapatite Inorganic materials 0.000 description 19
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 19
210000004027 cell Anatomy 0.000 description 16
239000002131 composite material Substances 0.000 description 16
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
206010017076 Fracture Diseases 0.000 description 14
238000003786 synthesis reaction Methods 0.000 description 14
239000000292 calcium oxide Substances 0.000 description 13
230000035876 healing Effects 0.000 description 13
239000010410 layer Substances 0.000 description 13
DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 13
230000011164 ossification Effects 0.000 description 12
241000906034 Orthops Species 0.000 description 11
229940088710 antibiotic agent Drugs 0.000 description 11
239000001506 calcium phosphate Substances 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 11
238000000338 in vitro Methods 0.000 description 11
230000005764 inhibitory process Effects 0.000 description 11
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 11
108091003079 Bovine Serum Albumin Proteins 0.000 description 10
239000004793 Polystyrene Substances 0.000 description 10
230000000278 osteoconductive effect Effects 0.000 description 10
229920002223 polystyrene Polymers 0.000 description 10
235000012239 silicon dioxide Nutrition 0.000 description 10
239000007787 solid Substances 0.000 description 10
241000894006 Bacteria Species 0.000 description 9
208000010392 Bone Fractures Diseases 0.000 description 9
210000002805 bone matrix Anatomy 0.000 description 9
230000006870 function Effects 0.000 description 9
238000001228 spectrum Methods 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 8
102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 8
229940112869 bone morphogenetic protein Drugs 0.000 description 8
229940098773 bovine serum albumin Drugs 0.000 description 8
238000005266 casting Methods 0.000 description 8
238000001879 gelation Methods 0.000 description 8
239000007788 liquid Substances 0.000 description 8
230000002188 osteogenic effect Effects 0.000 description 8
230000002138 osteoinductive effect Effects 0.000 description 8
239000000126 substance Substances 0.000 description 8
DQWPFSLDHJDLRL-UHFFFAOYSA-N triethyl phosphate Chemical compound CCOP(=O)(OCC)OCC DQWPFSLDHJDLRL-UHFFFAOYSA-N 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
239000007983 Tris buffer Substances 0.000 description 7
KHMFYFVXTICBEL-UHFFFAOYSA-N [4-(4-fluorophenyl)phenyl]boronic acid Chemical compound C1=CC(B(O)O)=CC=C1C1=CC=C(F)C=C1 KHMFYFVXTICBEL-UHFFFAOYSA-N 0.000 description 7
229910000389 calcium phosphate Inorganic materials 0.000 description 7
235000011010 calcium phosphates Nutrition 0.000 description 7
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 6
102000013275 Somatomedins Human genes 0.000 description 6
238000003556 assay Methods 0.000 description 6
239000004068 calcium phosphate ceramic Substances 0.000 description 6
230000001186 cumulative effect Effects 0.000 description 6
239000002245 particle Substances 0.000 description 6
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
238000012360 testing method Methods 0.000 description 6
238000011282 treatment Methods 0.000 description 6
102000008186 Collagen Human genes 0.000 description 5
108010035532 Collagen Proteins 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
210000002449 bone cell Anatomy 0.000 description 5
230000008468 bone growth Effects 0.000 description 5
229920001436 collagen Polymers 0.000 description 5
239000000284 extract Substances 0.000 description 5
230000012010 growth Effects 0.000 description 5
230000001976 improved effect Effects 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
239000012071 phase Substances 0.000 description 5
229920001817 Agar Polymers 0.000 description 4
108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 4
102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 4
238000001157 Fourier transform infrared spectrum Methods 0.000 description 4
BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 4
239000008272 agar Substances 0.000 description 4
229940121363 anti-inflammatory agent Drugs 0.000 description 4
239000002260 anti-inflammatory agent Substances 0.000 description 4
210000000845 cartilage Anatomy 0.000 description 4
230000007423 decrease Effects 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
238000002149 energy-dispersive X-ray emission spectroscopy Methods 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
230000008020 evaporation Effects 0.000 description 4
229910052500 inorganic mineral Inorganic materials 0.000 description 4
238000003760 magnetic stirring Methods 0.000 description 4
238000012423 maintenance Methods 0.000 description 4
239000011707 mineral Substances 0.000 description 4
235000010755 mineral Nutrition 0.000 description 4
210000000963 osteoblast Anatomy 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
229910000391 tricalcium phosphate Inorganic materials 0.000 description 4
229940078499 tricalcium phosphate Drugs 0.000 description 4
108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 3
102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 3
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
102000018997 Growth Hormone Human genes 0.000 description 3
108010051696 Growth Hormone Proteins 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
241000191967 Staphylococcus aureus Species 0.000 description 3
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
229940035676 analgesics Drugs 0.000 description 3
230000008901 benefit Effects 0.000 description 3
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
239000012620 biological material Substances 0.000 description 3
239000001110 calcium chloride Substances 0.000 description 3
235000011148 calcium chloride Nutrition 0.000 description 3
229910001628 calcium chloride Inorganic materials 0.000 description 3
BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
239000000919 ceramic Substances 0.000 description 3
230000008859 change Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
238000009826 distribution Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
239000000122 growth hormone Substances 0.000 description 3
238000002513 implantation Methods 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
210000002901 mesenchymal stem cell Anatomy 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
230000006911 nucleation Effects 0.000 description 3
238000010899 nucleation Methods 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
239000000047 product Substances 0.000 description 3
239000012488 sample solution Substances 0.000 description 3
239000012086 standard solution Substances 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
239000002344 surface layer Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
235000019731 tricalcium phosphate Nutrition 0.000 description 3
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
229930182566 Gentamicin Natural products 0.000 description 2
102000002265 Human Growth Hormone Human genes 0.000 description 2
108010000521 Human Growth Hormone Proteins 0.000 description 2
239000000854 Human Growth Hormone Substances 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
102100026632 Mimecan Human genes 0.000 description 2
101800002327 Osteoinductive factor Proteins 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
239000011149 active material Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000003463 adsorbent Substances 0.000 description 2
210000001909 alveolar process Anatomy 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
239000008366 buffered solution Substances 0.000 description 2
239000006227 byproduct Substances 0.000 description 2
ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
239000004568 cement Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
210000001612 chondrocyte Anatomy 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000007797 corrosion Effects 0.000 description 2
238000005260 corrosion Methods 0.000 description 2
230000008021 deposition Effects 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
238000010828 elution Methods 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
230000035194 endochondral ossification Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
210000003722 extracellular fluid Anatomy 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
239000007789 gas Substances 0.000 description 2
229960002518 gentamicin Drugs 0.000 description 2
239000002241 glass-ceramic Substances 0.000 description 2
229920002674 hyaluronan Polymers 0.000 description 2
229960003160 hyaluronic acid Drugs 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000003993 interaction Effects 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
239000013335 mesoporous material Substances 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
230000004820 osteoconduction Effects 0.000 description 2
230000004819 osteoinduction Effects 0.000 description 2
210000004663 osteoprogenitor cell Anatomy 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
230000008439 repair process Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
229960001866 silicon dioxide Drugs 0.000 description 2
239000012890 simulated body fluid Substances 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000003980 solgel method Methods 0.000 description 2
238000000527 sonication Methods 0.000 description 2
241000894007 species Species 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
230000035882 stress Effects 0.000 description 2
239000000758 substrate Substances 0.000 description 2
229920002994 synthetic fiber Polymers 0.000 description 2
239000003104 tissue culture media Substances 0.000 description 2
230000017423 tissue regeneration Effects 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
238000003260 vortexing Methods 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
241000234282 Allium Species 0.000 description 1
235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
108010081589 Becaplermin Proteins 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 1
108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 description 1
108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
101150021185 FGF gene Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 1
108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010073713 Musculoskeletal injury Diseases 0.000 description 1
241000772415 Neovison vison Species 0.000 description 1
102000004067 Osteocalcin Human genes 0.000 description 1
108090000573 Osteocalcin Proteins 0.000 description 1
206010031252 Osteomyelitis Diseases 0.000 description 1
102000009890 Osteonectin Human genes 0.000 description 1
108010077077 Osteonectin Proteins 0.000 description 1
102000004264 Osteopontin Human genes 0.000 description 1
108010081689 Osteopontin Proteins 0.000 description 1
208000006735 Periostitis Diseases 0.000 description 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
229910052770 Uranium Inorganic materials 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000003377 acid catalyst Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000007605 air drying Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
238000005275 alloying Methods 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229910052586 apatite Inorganic materials 0.000 description 1
238000001479 atomic absorption spectroscopy Methods 0.000 description 1
238000005452 bending Methods 0.000 description 1
230000027455 binding Effects 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
238000006065 biodegradation reaction Methods 0.000 description 1
230000033558 biomineral tissue development Effects 0.000 description 1
239000006161 blood agar Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000010478 bone regeneration Effects 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
108010009896 bone resorption factor Proteins 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229940003871 calcium ion Drugs 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
230000022159 cartilage development Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
229940106164 cephalexin Drugs 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000011382 collagen catabolic process Effects 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000013267 controlled drug release Methods 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
238000005336 cracking Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
238000009795 derivation Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000000539 dimer Substances 0.000 description 1
229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000004821 effect on bone Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
102000013373 fibrillar collagen Human genes 0.000 description 1
108060002894 fibrillar collagen Proteins 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000000855 fungicidal effect Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
ZBKIUFWVEIBQRT-UHFFFAOYSA-N gold(1+) Chemical compound [Au+] ZBKIUFWVEIBQRT-UHFFFAOYSA-N 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
210000004124 hock Anatomy 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
238000011532 immunohistochemical staining Methods 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
238000005567 liquid scintillation counting Methods 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000000155 melt Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000009681 mesenchymal cell proliferation Effects 0.000 description 1
229910044991 metal oxide Inorganic materials 0.000 description 1
150000004706 metal oxides Chemical class 0.000 description 1
NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000001002 morphogenetic effect Effects 0.000 description 1
230000008450 motivation Effects 0.000 description 1
229960000808 netilmicin Drugs 0.000 description 1
ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000000399 orthopedic effect Effects 0.000 description 1
230000001582 osteoblastic effect Effects 0.000 description 1
210000002997 osteoclast Anatomy 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000011236 particulate material Substances 0.000 description 1
VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
230000003239 periodontal effect Effects 0.000 description 1
210000003460 periosteum Anatomy 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
108010017843 platelet-derived growth factor A Proteins 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000035752 proliferative phase Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000001878 scanning electron micrograph Methods 0.000 description 1
238000004626 scanning electron microscopy Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229910052814 silicon oxide Inorganic materials 0.000 description 1
239000002356 single layer Substances 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
239000011343 solid material Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
230000019635 sulfation Effects 0.000 description 1
238000005670 sulfation reaction Methods 0.000 description 1
238000005211 surface analysis Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000008685 targeting Effects 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
LFQCEHFDDXELDD-UHFFFAOYSA-N tetramethyl orthosilicate Chemical compound CO[Si](OC)(OC)OC LFQCEHFDDXELDD-UHFFFAOYSA-N 0.000 description 1
230000025366 tissue development Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/30—Inorganic materials
- A61L27/306—Other specific inorganic materials not covered by A61L27/303 - A61L27/32
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C4/00—Compositions for glass with special properties
- C03C4/0007—Compositions for glass with special properties for biologically-compatible glass
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30667—Features concerning an interaction with the environment or a particular use of the prosthesis
- A61F2002/30677—Means for introducing or releasing pharmaceutical products, e.g. antibiotics, into the body
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Inorganic Chemistry (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oral & Maxillofacial Surgery (AREA)
Transplantation (AREA)
Zoology (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Geochemistry & Mineralogy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Materials Engineering (AREA)
Vascular Medicine (AREA)
Materials For Medical Uses (AREA)
Steroid Compounds (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Glass Compositions (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

IL11477095A 1994-07-27 1995-07-27 Controlled release carriers of bioactive silica-based glass comprising biologically active molecules, method for their preparation and compositions containing them IL114770A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US28105594A	1994-07-27	1994-07-27
US40604795A	1995-03-17	1995-03-17
US08/477,585 US5591453A (en)	1994-07-27	1995-06-07	Incorporation of biologically active molecules into bioactive glasses

Publications (2)

Publication Number	Publication Date
IL114770A0 IL114770A0 (en)	1995-11-27
IL114770A true IL114770A (en)	2002-12-01

Family

ID=27403198

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL11477095A IL114770A (en)	1994-07-27	1995-07-27	Controlled release carriers of bioactive silica-based glass comprising biologically active molecules, method for their preparation and compositions containing them

Country Status (11)

Country	Link
US (1)	US5591453A (de)
EP (1)	EP0772436B1 (de)
JP (1)	JPH10503210A (de)
AT (1)	ATE235230T1 (de)
AU (1)	AU3147095A (de)
CA (1)	CA2195680A1 (de)
DE (1)	DE69530086T2 (de)
ES (1)	ES2194919T3 (de)
IL (1)	IL114770A (de)
TW (1)	TW448051B (de)
WO (1)	WO1996003117A1 (de)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6537574B1 (en)	1992-02-11	2003-03-25	Bioform, Inc.	Soft tissue augmentation material
US7060287B1 (en) *	1992-02-11	2006-06-13	Bioform Inc.	Tissue augmentation material and method
US7968110B2 (en) *	1992-02-11	2011-06-28	Merz Aesthetics, Inc.	Tissue augmentation material and method
US6582728B1 (en) *	1992-07-08	2003-06-24	Inhale Therapeutic Systems, Inc.	Spray drying of macromolecules to produce inhaleable dry powders
US6673335B1 (en) *	1992-07-08	2004-01-06	Nektar Therapeutics	Compositions and methods for the pulmonary delivery of aerosolized medicaments
ATE220327T1 (de) *	1992-09-29	2002-07-15	Inhale Therapeutic Syst	Pulmonale abgabe von aktiven fragmenten des parathormons
US6022748A (en) *	1997-08-29	2000-02-08	Sandia Corporation - New Mexico Regents Of The University Of California	Sol-gel matrices for direct colorimetric detection of analytes
ES2218543T3 (es) *	1994-03-07	2004-11-16	Nektar Therapeutics	Procedimiento y preparacion para la administracion de insulina por via pulmonar.
US20030113273A1 (en) *	1996-06-17	2003-06-19	Patton John S.	Methods and compositions for pulmonary delivery of insulin
NZ285664A (en) *	1994-05-18	1998-07-28	Inhale Therapeutic Syst	Dry powder interferon composition adapted for pulmonary delivery
US5817327A (en) *	1994-07-27	1998-10-06	The Trustees Of The University Of Pennsylvania	Incorporation of biologically active molecules into bioactive glasses
US6290991B1 (en)	1994-12-02	2001-09-18	Quandrant Holdings Cambridge Limited	Solid dose delivery vehicle and methods of making same
US6224913B1 (en)	1996-05-09	2001-05-01	The Trustees Of The University Of Pennsylvania	Conditioning of bioactive glass surfaces in protein containing solutions
US5830480A (en) *	1996-05-09	1998-11-03	The Trustees Of The University Of Pennsylvania	Stabilization of sol-gel derived silica-based glass
US6416774B1 (en) *	1996-05-09	2002-07-09	The Trustees Of The University Of Pennsyvania	Hollow bone mineral-like calcium phosphate particles
US6764690B2 (en) *	1996-05-29	2004-07-20	Delsitech Oy	Dissolvable oxides for biological applications
DK0906243T4 (da) *	1996-05-29	2009-06-08	Delsitech Oy	Oplöselige oxider til biologiske anvendelser
US5964807A (en) *	1996-08-08	1999-10-12	Trustees Of The University Of Pennsylvania	Compositions and methods for intervertebral disc reformation
US5834008A (en)	1996-09-19	1998-11-10	U.S. Biomaterials Corp.	Composition and method for acceleration of wound and burn healing
US6756060B1 (en)	1996-09-19	2004-06-29	Usbiomaterials Corp.	Anti-inflammatory and antimicrobial uses for bioactive glass compositions
ZA9711732B (en)	1996-12-31	1998-12-28	Quadrant Holdings Cambridge	Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
US9155496B2 (en)	1997-03-04	2015-10-13	Dexcom, Inc.	Low oxygen in vivo analyte sensor
US5945360A (en) *	1997-03-28	1999-08-31	Johns Manville International, Inc.	Biosoluble pot and marble-derived fiberglass
US5874101A (en) *	1997-04-14	1999-02-23	Usbiomaterials Corp.	Bioactive-gel compositions and methods
WO1998047547A1 (en) *	1997-04-22	1998-10-29	Washington Research Foundation	Trap-coated bone grafts and prostheses
US20030035778A1 (en) *	1997-07-14	2003-02-20	Robert Platz	Methods and compositions for the dry powder formulation of interferon
US6077987A (en) *	1997-09-04	2000-06-20	North Shore-Long Island Jewish Research Institute	Genetic engineering of cells to enhance healing and tissue regeneration
US6565885B1 (en)	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
US20060165606A1 (en)	1997-09-29	2006-07-27	Nektar Therapeutics	Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) *	1997-09-29	2001-10-30	Inhale Therapeutic Systems, Inc.	Stabilized preparations for use in metered dose inhalers
US5972384A (en) *	1997-10-01	1999-10-26	University Of Maryland, Baltimore	Use of biologically active glass as a drug delivery system
US6090399A (en) *	1997-12-11	2000-07-18	Rohm And Haas Company	Controlled release composition incorporating metal oxide glass comprising biologically active compound
FI980032A0 (fi) *	1998-01-09	1998-01-09	Heikki Matti Eemeli Rauvala	Ny anvaendning av en heparin bindande, med tillvaext foerknippad molekyl
US6696258B1 (en) *	1998-01-20	2004-02-24	Drexel University	Mesoporous materials and methods of making the same
US6423343B1 (en)	1998-01-23	2002-07-23	Usbiomaterials Corporation	Bioactive glass treatment of inflammation in skin conditions
US5958430A (en) *	1998-02-20	1999-09-28	Battelle Memorial Institute	Thin film composition with biological substance and method of making
GB9808052D0 (en) *	1998-04-17	1998-06-17	Secr Defence	Implants for administering substances and methods of producing implants
US5968253A (en) *	1998-07-31	1999-10-19	Norian Corporation	Calcium phosphate cements comprising antimicrobial agents
EP2338448A3 (de) *	1998-09-10	2013-12-11	USBiomaterials Corporation	Antiinflammatorische und antimikrobielle Verwendungen von bioaktiven Glaszusammensetzungen
US6383519B1 (en) *	1999-01-26	2002-05-07	Vita Special Purpose Corporation	Inorganic shaped bodies and methods for their production and use
JP2002543108A (ja)	1999-04-29	2002-12-17	ユーエスバイオマテリアルズコーポレイション	抗炎症性生物活性ガラス微粒子
US6605293B1 (en) *	1999-05-20	2003-08-12	Trustees Of Boston University	Polymer re-inforced anatomically accurate bioactive protheses
AU5485200A (en)	1999-06-14	2001-01-02	Imperial College Innovations	Silver-containing, sol-gel derived bioglass compositions
US7118921B1 (en)	1999-06-24	2006-10-10	Mcmaster University	Incorporation and applications of biomolecular interactions within a carrier
CA2377560C (en) *	1999-06-24	2010-08-24	Mcmaster University	Incorporation and applications of biomolecular interactions within a carrier
US6458162B1 (en) *	1999-08-13	2002-10-01	Vita Special Purpose Corporation	Composite shaped bodies and methods for their production and use
US6303183B1 (en)	1999-11-08	2001-10-16	Aos Holding Company	Anti-microbial porcelain enamel coating
US20040009228A1 (en) *	1999-11-30	2004-01-15	Pertti Tormala	Bioabsorbable drug delivery system for local treatment and prevention of infections
US6579533B1 (en) *	1999-11-30	2003-06-17	Bioasborbable Concepts, Ltd.	Bioabsorbable drug delivery system for local treatment and prevention of infections
AUPQ573300A0 (en)	2000-02-21	2000-03-16	Australian Nuclear Science & Technology Organisation	Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use
JP4979109B2 (ja)	2000-04-21	2012-07-18	ゾル−ゲルテクノロジーズリミテッド	局所的有効成分の増強された配合安定性および送達を示す組成物
US7758888B2 (en) *	2000-04-21	2010-07-20	Sol-Gel Technologies Ltd.	Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
US8404217B2 (en) *	2000-05-10	2013-03-26	Novartis Ag	Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en)	2000-05-10	2011-01-18	Novartis Ag	Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7442388B2 (en)	2000-05-10	2008-10-28	Weers Jeffry G	Phospholipid-based powders for drug delivery
AU2001280934A1 (en) *	2000-07-28	2002-02-13	Alliance Pharmaceutical Corp.	Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
JP2004526749A (ja) *	2001-04-04	2004-09-02	デルシテクオサケユキチュア	生分解性キャリアおよびその製造方法
US20030031694A1 (en) *	2001-04-20	2003-02-13	3M Innovative Properties Company	Controlled release particles
EP1423091A4 (de) *	2001-08-10	2005-07-20	Univ California	Empfindlicher und schneller nachweis von pathogenen organismen und toxinen mit fluoreszierenden polymeren lipiden
EP1446086A1 (de) *	2001-11-08	2004-08-18	Sol-Gel Technologies Ltd.	Zusammensetzungen enthaltend öle mit einem höheren spezifischen gewicht als das spezifische gewicht von wasser
US7368102B2 (en)	2001-12-19	2008-05-06	Nektar Therapeutics	Pulmonary delivery of aminoglycosides
US20030220692A1 (en) *	2002-02-09	2003-11-27	Shapiro Irving M.	Preparations of nucleus pulposus cells and methods for their generation, identification, and use
US7613491B2 (en)	2002-05-22	2009-11-03	Dexcom, Inc.	Silicone based membranes for use in implantable glucose sensors
US8364229B2 (en)	2003-07-25	2013-01-29	Dexcom, Inc.	Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US8337893B2 (en) *	2002-07-10	2012-12-25	Florida Research Foundation, Inc, University Of	Sol-gel derived bioactive glass polymer composite
US20050008990A1 (en) *	2003-02-26	2005-01-13	Therics, Inc.	Method and system for repairing endosseous implants, such as with a bone graft implant
US7923030B2 (en) *	2003-03-14	2011-04-12	Sol-Gel Technologies, Inc.	Agent-encapsulating micro- and nanoparticles, methods for preparation of same and products containing same
JP5107573B2 (ja) *	2003-04-25	2012-12-26	ザペンステイトリサーチファウンデーション	増殖抑制性脂質由来生物活性化合物の全身送達方法およびシステム
US9763609B2 (en)	2003-07-25	2017-09-19	Dexcom, Inc.	Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
EA008771B1 (ru) *	2003-07-31	2007-08-31	Сол-Джел Текнолоджиз Лтд.	Микрокапсулы, заполненные активными ингредиентами, и способ их приготовления
US7591801B2 (en)	2004-02-26	2009-09-22	Dexcom, Inc.	Integrated delivery device for continuous glucose sensor
US9135402B2 (en)	2007-12-17	2015-09-15	Dexcom, Inc.	Systems and methods for processing sensor data
US7920906B2 (en)	2005-03-10	2011-04-05	Dexcom, Inc.	System and methods for processing analyte sensor data for sensor calibration
US9247900B2 (en)	2004-07-13	2016-02-02	Dexcom, Inc.	Analyte sensor
US7189263B2 (en)	2004-02-03	2007-03-13	Vita Special Purpose Corporation	Biocompatible bone graft material
DE112005000269T5 (de) *	2004-02-17	2007-01-25	Waters Investments Ltd., New Castle	Poröse Hybridmonolithmaterialien mit von der Oberfläche entfernten organischen Gruppen
US8808228B2 (en)	2004-02-26	2014-08-19	Dexcom, Inc.	Integrated medicament delivery device for use with continuous analyte sensor
EP1718564B1 (de) *	2004-02-27	2018-11-14	DelSiTech Oy	Verfahren zur herstellung von einstellbar bioresorbierbarem, nach einem sol-gel-verfahren hergestelltem sio2
US9220595B2 (en)	2004-06-23	2015-12-29	Orthovita, Inc.	Shapeable bone graft substitute and instruments for delivery thereof
WO2006127694A2 (en)	2004-07-13	2006-11-30	Dexcom, Inc.	Analyte sensor
US8989833B2 (en)	2004-07-13	2015-03-24	Dexcom, Inc.	Transcutaneous analyte sensor
GB0420016D0 (en)	2004-09-09	2004-10-13	Leuven K U Res & Dev	Controlled release oral delivery system
MX2007009430A (es) *	2005-02-03	2007-08-17	Cinv Ag	Materiales para suministro de farmacos producidos mediante la tecnologia de sol/gel.
EP1878044B1 (de) *	2005-04-27	2018-03-21	The Trustees of The University of Pennsylvania	Xerogel-filme zur kontrollierten freigabe pharmazeutisch aktiver moleküle
US20070031342A1 (en) *	2005-06-22	2007-02-08	Nektar Therapeutics	Sustained release microparticles for pulmonary delivery
AU2006274541B2 (en)	2005-08-02	2012-12-13	Sol-Gel Technologies Ltd.	Metal oxide coating of water insoluble ingredients
US20080254082A1 (en) *	2005-09-27	2008-10-16	Sol-Gel Technologies Ltd.	Methods for Crop Protection
US9757061B2 (en)	2006-01-17	2017-09-12	Dexcom, Inc.	Low oxygen in vivo analyte sensor
US20070184087A1 (en)	2006-02-06	2007-08-09	Bioform Medical, Inc.	Polysaccharide compositions for use in tissue augmentation
US20070254038A1 (en) *	2006-04-26	2007-11-01	The Trustees Of The University Of Pennsylvania	Microspheroidal Controlled Release Of Biomolecules
WO2007141590A1 (en) *	2006-06-06	2007-12-13	Universidad Autonoma Metropolitana	Sol-gel nanostructured titania reservoirs for use in the controlled release of drugs in the central nervous system and method of synthesis
AU2007265379B9 (en)	2006-06-29	2014-05-29	Orthovita, Inc.	Bioactive bone graft substitute
BRPI0808163A2 (pt)	2007-02-01	2014-11-04	Sol Gel Technologies Ltd	Composição para aplicação tópica, métodos para tratar uma condição de superfície em um indivíduo, para preparar uma composição, e para usar o kit, e, kit
KR20090121291A (ko) *	2007-02-01	2009-11-25	솔-겔 테크놀로지스 리미티드	산화금속 코팅을 포함한 입자의 제조방법 및 산화금속 코팅을 포함한 입자
FI20070174A0 (fi) *	2007-02-28	2007-02-28	Delsitech Oy	Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt
US20200037874A1 (en)	2007-05-18	2020-02-06	Dexcom, Inc.	Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US20080306434A1 (en)	2007-06-08	2008-12-11	Dexcom, Inc.	Integrated medicament delivery device for use with continuous analyte sensor
JP5509073B2 (ja)	2007-07-12	2014-06-04	ディスクジェニクス	ヒト円板組織
EP2227132B1 (de)	2007-10-09	2023-03-08	DexCom, Inc.	Integriertes insulin-abgabesystem mit kontinuierlichem glucosesensor
US8417312B2 (en)	2007-10-25	2013-04-09	Dexcom, Inc.	Systems and methods for processing sensor data
US9839395B2 (en)	2007-12-17	2017-12-12	Dexcom, Inc.	Systems and methods for processing sensor data
US20090324695A1 (en) *	2008-05-30	2009-12-31	Paul Ducheyne	Biocompatible polymer ceramic composite matrices
FR2933703B1 (fr) *	2008-07-11	2012-08-17	Commissariat Energie Atomique	Detecteurs nanoporeux de composes aromatiques monocycliques et autres polluants
AU2010246067B2 (en) *	2009-05-04	2016-07-07	Eyepoint Pharmaceuticals Us, Inc.	Porous silicon drug-eluting particles
US9399086B2 (en) *	2009-07-24	2016-07-26	Warsaw Orthopedic, Inc	Implantable medical devices
EP2629780A4 (de)	2010-10-20	2014-10-01	206 Ortho Inc	Implantierbares polymer für knochen- und gefässläsionen
US11058796B2 (en)	2010-10-20	2021-07-13	206 Ortho, Inc.	Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
US10525168B2 (en)	2010-10-20	2020-01-07	206 Ortho, Inc.	Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
US11207109B2 (en)	2010-10-20	2021-12-28	206 Ortho, Inc.	Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
US11291483B2 (en)	2010-10-20	2022-04-05	206 Ortho, Inc.	Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants
US11484627B2 (en)	2010-10-20	2022-11-01	206 Ortho, Inc.	Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
US9320601B2 (en)	2011-10-20	2016-04-26	206 Ortho, Inc.	Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants
US10525169B2 (en)	2010-10-20	2020-01-07	206 Ortho, Inc.	Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
RU2640918C2 (ru)	2010-11-01	2018-01-12	Псивида Юэс, Инк.	Биоразлагаемые устройства на основе кремния для доставки терапевтических агентов
US8551525B2 (en) *	2010-12-23	2013-10-08	Biostructures, Llc	Bone graft materials and methods
CN105050708A (zh)	2012-11-14	2015-11-11	格雷斯公司	含有生物活性材料与无序无机氧化物的组合物
US9687465B2 (en)	2012-11-27	2017-06-27	Sol-Gel Technologies Ltd.	Compositions for the treatment of rosacea
EP2968571A4 (de)	2013-03-15	2016-09-07	Psivida Inc	Biologisch abbaubare zusammensetzungen auf siliciumbasis zur abgabe therapeutischer mittel
JP2016525379A (ja)	2013-05-23	2016-08-25	２０６オーソ，インコーポレーテッド	複合材インプラントの提供および使用を含む、骨折を治療するための、ならびに／または、骨を補強および／もしくは増強するための方法および装置
FR3006195B1 (fr) *	2013-06-03	2018-03-02	Centre National De La Recherche Scientifique	Implant a porosite controlee
US10195305B2 (en)	2015-03-24	2019-02-05	Orthovita, Inc.	Bioactive flowable wash-out resistant bone graft material and method for production thereof
PL3634433T3 (pl) *	2017-06-01	2024-03-04	Fundació Institut De Bioenginyeria De Catalunya (Ibec)	Cząstki wapnia o kontrolowanym uwalnianiu jonów, sposób ich wytwarzania i zastosowanie
WO2019012537A1 (en)	2017-07-12	2019-01-17	Sol-Gel Technologies Ltd	COMPOSITIONS COMPRISING ENCAPSULATED TRETTINOIN
US11331022B2 (en)	2017-10-24	2022-05-17	Dexcom, Inc.	Pre-connected analyte sensors
EP3928687B1 (de)	2017-10-24	2024-06-26	Dexcom, Inc.	Tragbare vorrichtung mit vorverbundenem analytsensor
WO2023077447A1 (zh) *	2021-11-05	2023-05-11	中国科学院过程工程研究所	环肽玻璃及含有环肽的药物组合物玻璃
CN118930022B (zh) *	2024-10-15	2025-03-18	沈阳市口腔医院	一种45s5生物活性玻璃的溶胶凝胶制备方法及其产品

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE222498C (de) *
DE248351C (de) *
DE3134728A1 (de) *	1981-09-02	1983-03-10	Jürgen Dr.med. 5024 Brauweiler Eitenmüller	Material fuer knochenimplantate, verfahren zu seiner herstellung und seine verwendung
US4851150A (en) *	1984-02-27	1989-07-25	University Of Florida	Drying control chemical additives for rapid production of large sol-gel derived silicon, boron and sodium containing monoliths
DE3423667A1 (de) *	1984-05-08	1985-11-28	Rüdiger Dipl.-Ing. 5204 Lohmar Scheunemann	Implantat fuer knochen- und zahnwurzelersatz mit spezieller uebergangsstruktur zwischen knochen und implantatkern und knochenseitig ganz oder teilweise resorbierbarer matrix
US4563350A (en) *	1984-10-24	1986-01-07	Collagen Corporation	Inductive collagen based bone repair preparations
US4849378A (en) *	1985-02-25	1989-07-18	University Of Florida	Ultraporous gel monoliths having predetermined pore sizes and their production
US4859525A (en) *	1985-02-25	1989-08-22	University Of Florida	Method for low temperature processing of lightweight SiC/SiO2 composites and products
DE3613213A1 (de) *	1986-04-18	1987-10-22	Merck Patent Gmbh	Tricalciumphosphat fuer implantationsmaterialien
US5344654A (en) *	1988-04-08	1994-09-06	Stryker Corporation	Prosthetic devices having enhanced osteogenic properties
US5108436A (en) *	1988-09-29	1992-04-28	Collagen Corporation	Implant fixation
US5207710A (en) *	1988-09-29	1993-05-04	Collagen Corporation	Method for improving implant fixation
US5296026A (en) *	1988-12-02	1994-03-22	Monroe Eugene A	Phosphate glass cement
US4976736A (en) *	1989-04-28	1990-12-11	Interpore International	Coated biomaterials and methods for making same
FR2651439B1 (fr) *	1989-09-06	1994-09-23	Fbfc International Sa Nv	Materiau bioreactif pour prothese ou implants composites.
US5071655A (en) *	1990-01-12	1991-12-10	Baylink David J	Pharmaceutical combination for treatment of bone-wasting diseases
IL93134A (en) *	1990-01-23	1997-11-20	Yissum Res Dev Co	Doped sol-gel glasses for obtaining chemical interactions
US5371018A (en) *	1990-01-23	1994-12-06	Yissum, Research Development Company Of The Hebrew University Of Jerusalem	Qualitative and quantitative processes for reactive chemicals in liquids using doped sol-gel glasses
US5074916A (en) *	1990-05-18	1991-12-24	Geltech, Inc.	Alkali-free bioactive sol-gel compositions
WO1991017777A2 (en) *	1990-05-22	1991-11-28	University Of Florida	Injectable bioactive glass compositions and methods for tissue reconstruction
DE4019617A1 (de) *	1990-06-20	1992-01-02	Thera Ges Fuer Patente	Implantierbares wirkstoffdepotmaterial
FR2668367B1 (fr) *	1990-10-26	1994-05-13	Centre Nal Recherc Scientifique	Medicament implantable a effet prolonge.
ZA923086B (en) *	1991-04-29	1993-10-28	South African Medical Research	A delivery system for biologicaly active growth or morphogenetic factors and a method for preparing such delivery system
JP3051945B2 (ja) *	1991-07-22	2000-06-12	大阪瓦斯株式会社	無機質均一微小球体、及びその製造方法
US5200334A (en) *	1991-08-13	1993-04-06	The Regents Of The University Of California	Sol-gel encapsulated enzyme
JPH05253286A (ja) *	1992-03-12	1993-10-05	Makoto Otsuka	骨修復材料
CA2142282A1 (en) *	1992-08-13	1994-03-03	Paul Ducheyne	Bioactive material template for in vitro synthesis of bone tissue
NO940913L (no) *	1993-03-26	1994-09-27	Bristol Myers Squibb Co	Preparater for kontrollert frigivelse av biologisk aktiv TGF-

1995
- 1995-06-07 US US08/477,585 patent/US5591453A/en not_active Expired - Fee Related
- 1995-07-26 DE DE69530086T patent/DE69530086T2/de not_active Expired - Fee Related
- 1995-07-26 JP JP8505948A patent/JPH10503210A/ja not_active Ceased
- 1995-07-26 WO PCT/US1995/009401 patent/WO1996003117A1/en not_active Ceased
- 1995-07-26 AT AT95927435T patent/ATE235230T1/de not_active IP Right Cessation
- 1995-07-26 CA CA002195680A patent/CA2195680A1/en not_active Abandoned
- 1995-07-26 EP EP95927435A patent/EP0772436B1/de not_active Expired - Lifetime
- 1995-07-26 ES ES95927435T patent/ES2194919T3/es not_active Expired - Lifetime
- 1995-07-26 AU AU31470/95A patent/AU3147095A/en not_active Abandoned
- 1995-07-27 IL IL11477095A patent/IL114770A/en not_active IP Right Cessation
- 1995-07-28 TW TW084107852A patent/TW448051B/zh not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA2195680A1 (en)	1996-02-08
ATE235230T1 (de)	2003-04-15
JPH10503210A (ja)	1998-03-24
IL114770A0 (en)	1995-11-27
WO1996003117A1 (en)	1996-02-08
AU3147095A (en)	1996-02-22
ES2194919T3 (es)	2003-12-01
EP0772436B1 (de)	2003-03-26
EP0772436A1 (de)	1997-05-14
TW448051B (en)	2001-08-01
DE69530086D1 (de)	2003-04-30
US5591453A (en)	1997-01-07
EP0772436A4 (de)	1998-04-15
DE69530086T2 (de)	2004-03-04

Legal Events

Date	Code	Title
2003-05-29	FF	Patent granted
2003-06-24	FF	Patent granted
2003-07-31	KB	Patent renewed
2006-04-10	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
EP0772436B1 (de)	2003-03-26	Aufnahme von biologisch aktiven molekülen in bioaktives glas
US5874109A (en)	1999-02-23	Incorporation of biological molecules into bioactive glasses
Piatti et al.	2024	Tailoring of bioactive glass and glass-ceramics properties for in vitro and in vivo response optimization: a review
Hum et al.	2012	Bioactive glasses as carriers for bioactive molecules and therapeutic drugs: a review
Verron et al.	2010	Calcium phosphate biomaterials as bone drug delivery systems: a review
Bodde et al.	2008	The kinetic and biological activity of different loaded rhBMP‐2 calcium phosphate cement implants in rats
Saravanapavan et al.	2004	Binary CaO–SiO2 gel‐glasses for biomedical applications
Fernandes et al.	2021	Calcium sulfate as a scaffold for bone tissue engineering: a descriptive review
JP5882997B2 (ja)	2016-03-09	骨移植片系
JP2000513714A (ja)	2000-10-17	ゾル―ゲル誘導シリカ系ガラス
KR20070030174A (ko)	2007-03-15	다공성 캐리어 및 적어도 하나의 피롤리돈을 함유하는 뼈조직 이식 물질 및 그것의 생산 방법 및 임플란트
US6224913B1 (en)	2001-05-01	Conditioning of bioactive glass surfaces in protein containing solutions
Pacheco et al.	2014	Tissue engineering scaffold for sequential release of vancomycin and rhBMP2 to treat bone infections
El‐Ghannam et al.	2005	Nanoporous delivery system to treat osteomyelitis and regenerate bone: gentamicin release kinetics and bactericidal effect
El‐Ghannam et al.	2004	Cyclosilicate nanocomposite: A novel resorbable bioactive tissue engineering scaffold for BMP and bone‐marrow cell delivery
US20150283300A1 (en)	2015-10-08	Bioactive glasses with surface immobilized peptides and uses thereof
Stanić	2017	Variation in properties of bioactive glasses after surface modification
Daculsi et al.	2014	The essential role of calcium phosphate bioceramics in bone regeneration
Zhang et al.	2020	Repair of segmental rabbit radial defects with Cu/Zn co-doped calcium phosphate scaffolds incorporating GDF-5 carrier
Borges et al.	2016	Biocompatible Glasses for controlled release technology
Zhang et al.	2014	Dual-functional biomaterials for bone regeneration and infection control
Jones	2015	Sol–gel materials for biomedical applications
WO2002060503A1 (en)	2002-08-08	Resorbable bone cement containing active agents
Verron et al.	2010	Calcium phosphate ceramics as bone drug-combined devices
US7223414B1 (en)	2007-05-29	Silica-calcium phosphate bioactive composite for improved synthetic graft resorbability and tissue regeneration